STK10 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL54436	0.36	5/20
Tivozanib (SCHEMBL172883)	1.00	2/20
SCHEMBL147331	0.91	2/20
SCHEMBL141930	0.90	2/20
Erlotinib (SCHEMBL33835)	0.89	2/20
SCHEMBL142206	0.85	2/20
SCHEMBL144842	0.80	2/20
SCHEMBL144192	0.75	2/20
SCHEMBL144525	0.71	2/20
SCHEMBL146263	0.71	2/20
SCHEMBL141676	0.69	2/20
SCHEMBL145500	0.69	2/20
SCHEMBL167925	0.69	2/20
SCHEMBL144281	0.68	2/20
SCHEMBL141372	0.68	2/20
SCHEMBL145902	0.67	2/20
SCHEMBL146743	0.67	2/20
SCHEMBL144785	0.67	2/20
SCHEMBL147096	0.63	2/20
SCHEMBL144209	0.62	2/20

Clinical trials — most relevant to STK10 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions	PHASE4	UNKNOWN
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER	PHASE2/PHASE3	RECRUITING
Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus	PHASE2	COMPLETED
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma	PHASE2	COMPLETED
Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes	PHASE2	COMPLETED
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients	PHASE2	COMPLETED
Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma	PHASE2	UNKNOWN
Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer	PHASE2	COMPLETED
Bempedoic Acid Therapy for Polycystic Kidney Disease	PHASE2	NOT_YET_RECRUITING
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).	PHASE1	ACTIVE_NOT_RECRUITING
Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer	PHASE1	COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	PHASE1	COMPLETED
Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy	PHASE1	UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KN510, KN713	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
Exercise in Type 1 Diabetes Mellitus	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
New Genes in the Carcinogenesis of Colorectal Cancer	nan	UNKNOWN
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a STK10 binder may also engage these)

Protein	Name	Similarity
F1NBT0	—	1.000	F1NBT0 →
O55098	—	1.000	O55098 →
Q7SY52	—	1.000	Q7SY52 →
E1BK52	—	0.999	E1BK52 →
B7ZR30	—	0.999	B7ZR30 →
E9PTG8	—	0.999	E9PTG8 →
Q0IHQ8	—	0.997	Q0IHQ8 →
P46549	—	0.991	P46549 →
Q7ZYJ0	—	0.990	Q7ZYJ0 →
Q6GPK9	—	0.990	Q6GPK9 →
O88664	—	0.990	O88664 →
TAOK1	Serine/threonine-protein kinase TAO1	0.989	landscape →
Q8BX57	—	0.987	Q8BX57 →
Q53UA7	—	0.987	Q53UA7 →
O43150	—	0.987	O43150 →
D3ZA12	—	0.987	D3ZA12 →
Q5F2E8	—	0.987	Q5F2E8 →
CDC42BPA	Serine/threonine-protein kinase MRCK alpha	0.986	landscape →
CDC42BPB	Serine/threonine-protein kinase MRCK beta	0.986	landscape →
Q7SIG6	—	0.986	Q7SIG6 →
Q80U87	—	0.986	Q80U87 →
G5EFD2	—	0.986	G5EFD2 →
Q6NU21	—	0.986	Q6NU21 →
O54874	—	0.986	O54874 →
O54988	—	0.986	O54988 →
Q95RG8	—	0.986	Q95RG8 →
Q6ZPS6	—	0.985	Q6ZPS6 →
A3KFM7	—	0.985	A3KFM7 →
Q7Z3E5	—	0.985	Q7Z3E5 →
Q9I9E0	—	0.985	Q9I9E0 →